TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07604324: A Two-part, Randomized, Participant- and Investigator-blinded, Placebo Controlled First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of DCY636 in a Single Ascending Dose Part in Healthy Par

Sponsor: Novartis Pharmaceuticals · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 63 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,614,080

Rescue Site Savings

+$3,701,784

Unlock Full NCT07604324 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07604324 Rescue Dossier →